Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trivirus-Specific CTLs for Persistent Viral Infections Post-HSCT
NCT00711035Phase 2Completed
- Sponsor
- Baylor College of Medicine
- Start
- Nov 2008
- Primary completion
- Oct 2012
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Trivirus-specific cytotoxic T-lymphocytes in cytomegalovirus infection (CMV), Epstein-Barr virus infection, adenovirus infection, sponsored by Baylor College of Medicine. Started Nov 2008; status: completed.
02
Drugs
Trivirus-specific cytotoxic T-lymphocytes
03
Conditions
cytomegalovirus infection (CMV)Epstein-Barr virus infectionadenovirus infection
Beyond the preview
Go deeper on NCT00711035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00711035.